KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Consolidated Net Income: 2011-2025

Historic Consolidated Net Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$45.1 million.

  • Supernus Pharmaceuticals' Consolidated Net Income fell 217.20% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 131.95%. This contributed to the annual value of $73.9 million for FY2024, which is 5512.84% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Consolidated Net Income stood at -$45.1 million, which was down 300.53% from $22.5 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Consolidated Net Income peaked at $38.5 million during Q3 2024, and registered a low of -$45.1 million during Q3 2025.
  • For the 3-year period, Supernus Pharmaceuticals' Consolidated Net Income averaged around $3.7 million, with its median value being $1.2 million (2023).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first skyrocketed by 2,506.53% in 2024, then slumped by 9,641.13% in 2025.
  • Supernus Pharmaceuticals' Consolidated Net Income (Quarterly) stood at $2.4 million in 2021, then surged by 943.45% to $25.5 million in 2022, then slumped by 95.39% to $1.2 million in 2023, then skyrocketed by 1,208.68% to $15.4 million in 2024, then plummeted by 217.20% to -$45.1 million in 2025.
  • Its Consolidated Net Income stands at -$45.1 million for Q3 2025, versus $22.5 million for Q2 2025 and -$11.8 million for Q1 2025.